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Abstract
Objective: Although lower brain volume has been routinely observed in individuals with 
substance dependence compared with nondependent control subjects, the brain regions exhibiting 
lower volume have not been consistent across studies. In addition, it is not clear whether a 
common set of regions are involved in substance dependence regardless of the substance used or 
whether some brain volume effects are substance specific. Resolution of these issues may 
contribute to the identification of clinically relevant imaging biomarkers. Using pooled data from 
14 countries, the authors sought to identify general and substance-specific associations between 
dependence and regional brain volumes.
Method: Brain structure was examined in a mega-analysis of previously published data pooled 
from 23 laboratories, including 3,240 individuals, 2,140 of whom had substance dependence on 
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one of five substances: alcohol, nicotine, cocaine, methamphetamine, or cannabis. Subcortical 
volume and cortical thickness in regions defined by FreeSurfer were compared with nondependent 
control subjects when all sampled substance categories were combined, as well as separately, 
while controlling for age, sex, imaging site, and total intracranial volume. Because of extensive 
associations with alcohol dependence, a secondary contrast was also performed for dependence on 
all substances except alcohol. An optimized split-half strategy was used to assess the reliability of 
the findings.
Results: Lower volume or thickness was observed in many brain regions in individuals with 
substance dependence. The greatest effects were associated with alcohol use disorder. A set of 
affected regions related to dependence in general, regardless of the substance, included the insula 
and the medial orbitofrontal cortex. Furthermore, a support vector machine multivariate 
classification of regional brain volumes successfully classified individuals with substance 
dependence on alcohol or nicotine relative to nondependent control subjects.
Conclusions: The results indicate that dependence on a range of different substances shares a 
common neural substrate and that differential patterns of regional volume could serve as useful 
biomarkers of dependence on alcohol and nicotine.
The social and economic costs associated with problematic use of drugs and alcohol place 
an enormous burden on the individual and society (1−5). In the United States alone, the 
National Institute on Drug Abuse estimates that the costs associated with problematic 
substance use—including medical care, law enforcement, and lost productivity—exceed 
$700 billion per year (6). Substance dependence is characterized by a loss of control over 
drug and alcohol taking behavior, which contributes to high relapse rates (7−10). The 
therapeutic landscape would be radically altered by the identification of a set of biomarkers 
that could be used to estimate risk at various stages of the disorder—for example, the risk of 
transition from occasional to problematic patterns of use or risk of relapse after treatment—
and to prescribe the most appropriate treatments on the basis of the individual patient’s 
specific functional vulnerabilities (11, 12).
It remains to be determined whether regional differences in brain volume measured by MRI 
can provide clinically useful biomarkers of substance dependence. Although brain 
volumetric studies have routinely observed lower gray matter volume in individuals with 
substance dependence compared with healthy control subjects who do not have a substance 
dependence, the brain regions associated with dependence on a specific substance have not 
been consistent across studies (13−15). Since volumetric studies have tended to focus on one 
substance at a time, it is also not clear from this literature whether a shared set of brain areas 
will exhibit altered volume in all individuals with substance dependence regardless of the 
substance used. Human twin studies suggest that genetic vulnerability to substance 
dependence is accounted for principally by a shared set of variations regardless of the 
substance used, with proportionately smaller substance-specific effects (16). On the basis of 
preclinical research and data from other imaging modalities, several candidate brain regions 
have been proposed as playing a central role in substance dependence, including the 
striatum, the insula, and parts of the frontal cortex (reviewed in references 17−19).
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The authors of the present study joined to form an international working group within the 
framework of the Enhancing Neuro-Imaging Genetics Through Meta-Analysis (ENIGMA) 
project (20, 21) to overcome issues related to low statistical power in individual 
neuroimaging studies. This first project of the Addiction Working Group has pooled data 
from 23 laboratories in 14 countries and represents the largest study of brain volumetric data 
in substance dependence research to date. The objective was to identify general and 
substance-specific associations between dependence and regional brain volumes. The large 
sample size facilitated the adoption of a rigorous cross-validation method to address the 
widespread failure to replicate neuroimaging results, which has been noted in several recent 
influential reports (22, 23). In addition, a support vector machine classifier was used to 
explore patterns of regional brain volume that could potentially serve as disease biomarkers.
METHOD
Behavioral Phenotyping
All procedures were performed in accordance with the Declaration of Helsinki. Data sets 
from the working group were selected that assessed individuals for dependence on one of 
five substances: alcohol, nicotine, cocaine, metham-phetamine, and cannabis. A variety of 
diagnostic instruments were used to assess substance dependence (see Table S1 in the online 
supplement). Case and control data were gathered from 23 laboratories on 3,240 individuals, 
of whom 2,140 were diagnosed with current dependence on at least one of the five 
substances of interest. Individuals were excluded if they had a lifetime history of 
neurological disease, a current DSM-IV axis I diagnosis other than depressive and anxiety 
disorders, or any contraindication for MRI. Control subjects may have used addictive 
substances recreationally but were not diagnosed as dependent. Summary demographic 
statistics (sex distribution and mean age) on participants whose data passed the quality 
control steps described below are provided in Table 1. Site-specific summaries are provided 
in Table S1 in the online supplement.
Preparation of Structural MRI Data
Structural T1-weighted MRI brain scans were acquired from all participants. Scanner and 
acquisition details at each site are provided in Table S1 in the online supplement. Data were 
prepared in FreeSurfer (version 5.3), a fully automated MRI processing pipeline that 
identifies seven bilateral subcortical and 34 bilateral cortical regions of interest (24, 25). A 
majority of the data sets were prepared using CBRAIN, a network of high-performance 
computing facilities in Canada (26). The volume of subcortical regions of interest and mean 
thickness of cortical regions of interest served as the dependent measure in all analyses. The 
use of FreeSurfer in multisite analyses has been validated in previous ENIGMA studies 
(27−30) that established a standardized protocol of quality control procedures performed at 
each site (http://enigma.ini.usc.edu/protocols/imaging-protocols/). This includes detection of 
outliers and visual inspection of all data in a series of standard planes (for more details, see 
the Supplemental Methods section in the online supplement). An additional level of visual 
inspection was performed centrally at the University of Vermont on a randomly selected 
subsample of participants to ensure uniformity of quality control across sites.
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Linear Mixed-Effects Models With Cross-Validation
Differences in region-of-interest thickness or volume between substance-dependent 
participants and nondependent control subjects were assessed in each region of interest with 
two linear mixed-effects models, using SPSS Statistics for Windows, version 21.0 (IBM, 
Armonk, N.Y.). The linear mixed-effects model effectively accounts for site effects, 
including sites that did not collect data on nondependent control subjects (31). In model 1, 
substance-dependent individuals were treated as one group regardless of the substance used; 
individuals dependent on any of the five substances of interest were coded as “dependent” 
and control subjects as “nondependent.” Model 1 permitted inclusion of individuals who 
were dependent on more than one substance. In model 2, dependence on the five substances 
was coded as individual categories in a single fixed factor: individuals were coded as 
belonging to one and only one of six categories: “nondependent” or dependent on “alcohol,” 
“nicotine,” “cocaine,” “methamphetamine,” or “cannabis.” Model 2 did not permit inclusion 
of individuals who were dependent on more than one substance. In both models, MRI site 
was entered as a random factor, and sex, age, and total intracranial volume were included as 
covariates. Further analyses were performed to disconfirm the existence of a site-by-
diagnosis interaction (see the Supplemental Methods section in the online supplement).
The replicability of neuroimaging results has recently been brought into question (22, 23). 
The large sample size of the present study facilitated the adoption of an optimized split-half 
strategy to verify the reliability of effects. The data were split into two halves (a discovery 
data set and a replication data set) with statistically matched stratification for age, sex, and 
intracranial volume within each site and dependence status. Since each region of interest was 
analyzed separately, a false discovery rate method (the Benjamini-Hochberg procedure) was 
used to control for multiple comparisons on the first half of the data (the discovery data set). 
Associations discovered in the first half of the data are reported here as significant only if 
they were replicated in the second half of the data (the replication data set), that is, if the 
sign of the difference in means was the same and the null hypothesis had a probability 
<0.05.
General Versus Substance-Specific Dependence Effects
Model 2 permitted a comparison of the estimated marginal mean region-of-interest volume 
or thickness between nondependent control subjects and participants dependent on each 
substance. Significance was defined as in model 1. The large impact of alcohol dependence 
on the data (see the Results section) influenced the decision to examine whether dependence 
on any of the substances other than alcohol was related to differences in region-of-interest 
volume or thickness compared with nondependent control subjects. This was assessed with a 
secondary linear contrast within model 2 that grouped dependence on nicotine, cocaine, 
metham- phetamine, and cannabis (but not alcohol) in a comparison with nondependent 
control subjects.
Past-30-Day Use
Linear mixed-effects models were used to determine whether past-30-day nicotine or 
alcohol use was related to the volume or thickness of regions of interest identified by model 
Mackey et al. Page 4
Am J Psychiatry. Author manuscript; available in PMC 2019 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1 or 2 (i.e., those brain regions listed in Tables 2 and 3). (See the online supplement for more 
details.)
Support Vector Machine Classification
Support vector machine classification was implemented in MATLAB (MathWorks, Natick, 
Mass.) with a radial basis function kernel, tuned by parameter sweep in a 10-fold inner loop 
nested within an optimized split-half cross-validation (32) (for details, see the Supplemental 
Methods section in the online supplement). The radial basis function kernel facilitates the 
inclusion of nonlinear relationships in the classifier. In other words, the support vector 
machine can detect informative patterns in the data that may not be identified by traditional 
linear analyses such as models 1 and 2. To mitigate site, sex, age, and intracranial volume 
effects, region- of-interest data were residualized prior to classification. Five studies without 
control participants were excluded. Area under the receiver operating characteristic curve 
and corresponding p values based on equivalence with the Mann-Whitney U test were 
calculated to estimate generalizable classifier performance on the independent half of the 
data for each of two train-test scenarios (i.e., train on the first half, test on the second, and 
vice versa). A greater area under the receiver operating characteristic curve, which plots true 
positive rate against false positive rate, indicates a better separation of the substance-
dependent and nondependent groups. The significance threshold for area under the curve 
was defined as a p value of 0.05 in both classification scenarios. The top 20 features of each 
classification were determined by the greatest change in cost function resulting from their 
individual removal from the classification (33).
RESULTS
Basic demographic information (sex distribution and mean age) is provided in Table 1 and 
by site in Table S1 in the online supplement.
Model 1: Dependent Versus Nondependent Subjects
Subcortical volume in dependent individuals was significantly lower in the left and right 
hippocampus, the left and right amygdala, and the right nucleus accumbens (Table 2). Lower 
cortical thickness was observed in several areas, including the left and right insula, 
precentral gyrus, and supramarginal gyrus and the right medial orbitofrontal cortex. See 
Table 2 for a complete list and Supplemental Table S2 in the online supplement for an at-a-
glance summary.
Model 2: Substance Dependence Groups Compared Separately to Nondependent Control 
Subjects
All subcortical regions of interest identified in model 1 plus the right thalamus, the left and 
right putamen, the right globus pallidus, and the left nucleus accumbens had significantly 
lower volume in model 2 when alcohol-dependent participants were compared with 
nondependent control subjects. In addition, alcohol-dependent participants exhibited lower 
average thickness in 27 cortical regions of interest (Table 3, Figure 1). Cocaine dependence 
was associated with lower cortical thickness in only one brain region (see Table 3, Figure 1). 
No cross-validated differences in regional volume or thickness were significant for 
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dependence on nicotine, methamphetamine, or cannabis on their own. Since most effects 
were related to alcohol dependence, a secondary linear contrast was performed to explore 
the effect of removing alcohol from the analysis. The contrast compared participants 
dependent on any substance except alcohol against nondependent control subjects. It 
revealed that the left inferior parietal cortex and the insula bilaterally were significantly 
thinner in dependent individuals (see Table 3).
Substance-Specific Versus Shared Substance-General Effects
Three distinct patterns of results emerged, which are illustrated in Figure 2.
Pattern 1 (substance specific).—In most regions of interest where a significant 
difference was observed, the effect was demonstrated in model 2 to be related specifically to 
dependence on alcohol alone (27 regions of interest)—for example, the right nucleus 
accumbens (Figure 2)—or to both alcohol and cocaine—the right supramarginal gyrus (one 
region of interest) (see Figure 1, Tables 2 and 3).
Pattern 2 (substance general).—Six cortical regions of interest (e.g., the left 
supramarginal gyrus and the right medial orbitofrontal cortex) were associated with 
dependence in model 1 but were not significantly thinner in any one particular substance 
group relative to nondependent control subjects in model 2 (see Tables 2 and 3, Figures 1 
and 2).
Pattern 3 (substance general).—Three cortical regions of interest (the left inferior 
parietal cortex and the right and left insula) were significantly thinner when all dependent 
groups were compared with control subjects (model 1) and when all dependent groups 
except alcohol were contrasted against control subjects (model 2). In addition, the left insula 
was significantly thinner in the alcohol-dependent group alone relative to control subjects 
(Tables 2 and 3, Figures 1 and 2).
Past-30-Day Use
The volume of several subcortical regions of interest were negatively associated with 
past-30-day use of alcohol alter a false discovery rate correction for multiple comparisons: 
the left and right amygdala and nucleus accumbens, the right hippocampus, and the left 
globus pallidus. No brain regions were related to past-30-day nicotine use.
Support Vector Machine
The support vector machine produced a significant classification of alcohol- and nicotine-
dependent individuals relative to nondependent control subjects (Figure 3) in both halves of 
the data (p<0.05). The classification of cocaine-dependent individuals approached 
significance. The top 20 structural predictors distinguishing dependence on each substance 
from nondependent control subjects in each classification are listed in Table S3 in the online 
supplement.
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DISCUSSION
Subcortical volume or cortical thickness was significantly lower on average in substance-
dependent individuals compared with nondependent control subjects across widespread parts 
of the brain (i.e., 22 distinct regions of interest out of a total of 82) (see Table 2; see also 
Table S2 in the online supplement). Some of these differences were substance specific, and 
others appear to constitute a shared neural substrate associated with dependence regardless 
of the substance used (see Table 3 and Figure 1). A majority of the identified regions of 
interest were smaller or thinner specifically in the brains of alcohol-dependent individuals 
(e.g., the left and right posterior cingulate and superior frontal cortex). A more limited set of 
seven regions with lower cortical thickness across substance dependence groups included the 
left and right insula, the left inferior parietal cortex, the right medial orbitofrontal cortex, the 
left and right middle temporal gyrus, and the left supramarginal gyrus. No region of interest 
was significantly larger or thicker in substance-dependent individuals relative to control 
subjects. An unexpected finding of the study was the absence of substance-specific linear 
effects on brain volume related to nicotine, methamphetamine, or cannabis dependence 
despite the collection of large pooled samples. Also, the successful classification of 
individuals dependent on nicotine, alcohol, or cocaine using the support vector machine 
approach suggests that the development of clinically useful neuroimaging biomarkers of 
substance dependence may be more productive if based on broader patterns of brain function 
or structure rather than differences in unique brain regions considered alone.
The set of brain regions identified with substance dependence in general is supported by 
previous evidence. The insula performs a central role in the perception of the internal state 
of the body (34). Disruption of the insula could alter regulation of the intense positive and 
negative bodily states associated with drug taking and withdrawal, biasing the individual 
toward relapse as a maladaptive response to anticipated challenges to physiological 
homeostasis (35). It has been reported that smokers who have suffered brain damage 
involving the insula have subsequently lost the urge to smoke (36). The parietal cortex has 
been associated with attention and working memory (37, 38). Disruption of these processes 
could interfere with self-awareness about a substance use problem and the management of 
stressful situations. The medial orbitofrontal region of interest defined by FreeSurfer (also 
known as the ventromedial prefrontal cortex) encodes the subjective value of future rewards 
during decision making (39). Lesions of this region produce disadvantageous choices on 
gambling tasks that model real-life decisions (40). Altered neural activity in the insula and 
the medial orbital and parietal cortex has frequently been linked to substance dependence 
and may predict greater craving and risk of relapse (41−44). The present results support the 
idea that substance dependence is mediated by a shared set of mechanisms across substance 
groups. Indeed, twin studies suggest that vulnerability to substance dependence is accounted 
for principally by a shared set of genetic variations regardless of the substance used, with 
proportionately smaller substance- specific effects (16).
Although subtle in magnitude, the wide spatial distribution of alcohol-specific effects is a 
striking finding of the study. Alcohol consumption enjoys greater cultural acceptance in the 
countries from which the data for this study were sampled relative to the other substances 
examined (45). Alcohol is legal to buy and consume, and widely publicized government-
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sanctioned guidelines exist for “safe” low-dose use of alcohol. This tolerance of alcohol-
related health risks is unlike the cultural views toward any of the other substances 
investigated here, whose use even in small amounts is discouraged (45). It should be noted 
that lifetime exposure to each substance could not be uniformly assessed in the data sets 
used here. As a consequence, the scope of the alcohol dependence effects may in part be 
related to greater absolute consumption of alcohol relative to the other substances. It was 
possible to assess past-30-day use of nicotine and alcohol, a limited proxy of level of 
exposure, in a sizable minority of the data sets. Several subcortical regions of interest, such 
as the amygdala and the nucleus accumbens, were significantly smaller in individuals who 
reported the highest numbers of alcoholic drinks consumed in the past 30 days, consistent 
with the notion that greater exposure could be responsible for the magnitude of the observed 
alcohol effects. Further studies will be required to clarify whether the greater number of 
observed alcohol-specific effects relative to the other substances is related to differences in 
toxicity or total exposure.
It is also notable that, besides the seven brain regions associated with dependence in general, 
there were no drug-specific effects for dependence on nicotine, methamphetamine, and 
cannabis. Although cross-validation demonstrated that the volumetric differences observed 
were reliable, the effect sizes were uniformly small (see Tables 2 and 3). This suggests that 
the lack of consistency in the literature (13−15) may be related to the insufficient power of 
most studies to detect true effects. Other imaging modalities, such as task-based functional 
MRI (41−44) and higher-resolution structural imaging, may be required to detect reliable 
substance-specific nicotine, methamphetamine, or cannabis effects if they exist. It is also 
possible that substance dependence has multiple, heterogeneous interactions with brain 
volume that are not well assessed by simple linear analyses. Evidence for this is provided by 
the support vector machine classification.
The support vector machine classification found that the pattern of regional volume 
differences could be used successfully to distinguish between nondependent control subjects 
and individuals dependent on alcohol and nicotine. The transformation of the data with a 
radial basis function kernel prior to classification facilitated the detection of nonlinear 
patterns that cannot be detected by models 1 and 2. Additionally, the support vector machine 
can identify a multivariate pattern of effects across numerous regions of interest, each of 
which, in isolation, may not pass statistical threshold. Thus, the support vector machine 
detected useful information in the pattern of results that was not apparent from the linear 
analysis. The significant classifications suggest that the overall pattern of volumetric effects 
may contain useful clinical information that would not be apparent if only traditional 
univariate linear analyses were performed. While influential features in the classification 
partly overlapped with the regions of interest identified by the univariate analyses—for 
example, brain regions associated with alcohol dependence, such as the hippocampus and 
amygdala—additional regions not identified by the linear mixed effects analyses (i.e., model 
1 and model 2) were also involved (see Table S3 in the online supplement). Future efforts of 
the Addiction Working Group will include the incorporation of other imaging modalities 
with which it may be possible to distinguish individuals with dependence on additional 
substances, such as methamphetamine and cannabis, from nondependent control subjects. It 
would also be clinically useful to examine whether the support vector machine 
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classifications developed in this study offer an index of the strength of substance dependence 
in individuals who go on to recover or relapse. It is worth noting that current blood and urine 
tests do not identify dependence, as the machine learning classifier in the present study does, 
but rather detect, and to an extent quantify, recent substance use. While the present findings 
are preliminary and the support vector machine classifications should be tested on other 
independent samples, if brain volume is confirmed as a viable biomarker of dependence, or 
of biological risk of dependence, it could be used to plan how prevention and treatment 
resources are allocated to individual patients as well as, potentially, to track intervention 
success. A structural MRI scan in combination with other factors known to be related to 
substance use problems (e.g., change in employment or marital status, health issues) could 
be used to assess risk of transition to problematic patterns of use or to quantify the current 
degree of dependence, which would influence the intervention strategy.
Several factors limit the interpretation of the study findings. Different diagnostic instruments 
were used to assess substance dependence (see Table S1 in the online supplement). Although 
the validity of each of these instruments has been well established, variation between 
instruments could add noise to the measured behavioral phenotype. This, however, could be 
an advantage because the extrapolation of significant findings to the general population is 
also likely to be more robust by virtue of generalizing across different methods of 
assessment. The absence of nutrition and education information, which are potential 
confounders, also limits the interpretability of the results. A perennial concern with multisite 
studies is variation attributable to different scanners and acquisition protocols. This issue 
was mitigated by using a standard data extraction protocol developed by the ENIGMA 
project that has been validated in previous multisite reports (20, 28−30) and by the formal 
consideration of potential site differences in all statistical analyses. As discussed above, the 
degree of exposure to the various substances was not characterized uniformly across studies, 
which limits, for instance, the interpretation of the widespread alcohol effects and whether 
alcohol represents a greater source of toxicity than the other substances examined. It should 
be emphasized, however, that this study examined brain volumetric associations with 
dependence and not with total lifetime substance use. A beneficial outcome of this first 
study of the Addiction Working Group will be to raise awareness of the data needed to 
estimate the relation between brain volume and total exposure and, more generally, of the 
utility of uniform phenotypic data for data pooling. Greater consideration of how data may 
be used in international collaborations may influence the collection of data in future studies, 
which will increase their impact beyond their primary research focus. The PhenX Toolkit 
(https://www.phenxtoolkit.org/), for example, provides an extensive catalog of standardized 
measures expressly intended to facilitate secondary cross-study comparisons. Finally, co-
occurring substance use limits the interpretation of the findings. Pervasive recreational 
substance use is a general issue for all studies of human substance dependence. For example, 
it is likely epidemiologically that a methamphetamine user will be exposed to alcohol. 
Methamphetamine users who do not use any other addictive substance would be an unusual 
group who, in practice, would be difficult to identify but, more importantly, would not be 
characteristic of the real-world population of methamphetamine users—that is, there would 
be a selection bias. Unlike studies in animal models, it is not possible to randomly assign 
humans to groups with restricted exposure to one substance alone. The typical strategy, 
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which was used in the data sets included in this study, is to screen subjects for dependence 
on other substances but not to exclude for nondependent use of other substances.
The field of neuroimaging faces a crisis of relevance if published studies cannot be 
replicated, as noted in a series of reviews (22, 23). The authors of the present study joined to 
form a working group within the preexisting framework of the ENIGMA project to assemble 
a sufficiently large sample to overcome issues related to low statistical power that affect 
most individual neuroimaging studies. Using a rigorous cross-validation method, several 
brain regions were found to have a reliable association with substance dependence, including 
a shared set of regions across substances, such as the insula and the medial orbitofrontal 
cortex. Although the univariate analyses failed to identify linear effects in relation to 
dependence on nicotine, methamphetamine, and cannabis specifically, a machine learning 
algorithm, which was also able to detect nonlinear patterns in the data, successfully 
classified individuals dependent on alcohol or nicotine relative to nondependent control 
subjects. This suggests that the overall pattern of volumetric effects may contain more useful 
information with regard to the development of a neuroimaging biomarker of substance 
dependence than is revealed by the magnitude of single brain regions examined in isolation.
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FIGURE 1. Cortical Regions of Interest Exhibiting Substance- Specific or Shared Substance-
General Effects Displayed on the Surface of Partially Inflated Average Brainsa
a
 Substance specific: alcohol alone (green), alcohol and cocaine (purple); substance general: 
pattern 2 (yellow), pattern 3 (orange).
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FIGURE 2. Different Contributions of Dependence on the Five Substances Studied to the 
Association of Lower Volume or Thickness With Substance Dependencea
a
 For illustration purposes, both halves of the data (serving as the discovery and replication 
datasets) have been combined in the bar graphs. Three different patterns are illustrated. In 
pattern 1 (substance-specific effect), lower volume in the right nucleus accumbens was 
largely accounted for by dependence on alcohol alone. In pattern 2 (substance-general 
effect), volume in the left supramarginal gyrus was significantly lower in dependent 
compared with nondependent individuals (model 1) but was not significantly lower in any 
one particular substance group (model 2) compared with control subjects. In pattern 3 
(substance-general effect), volume in the left insula was lower when either the alcohol-
dependent group or the linear contrast of all substance groups except alcohol was compared 
with nondependent control subjects. Bars represent estimated marginal means expressed as 
percent difference from mean volume or thickness in nondependent control subjects. Error 
bars represent standard error. Meth=methamphetamine.
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FIGURE 3. Plot of Receiver Operating Characteristic Curves for the Support Vector Machine 
Classification of Individuals Dependent on One of Five Substances Relative to Nondependent 
Control Subjectsa
aThe area under the curve (AUC) is significant for alcohol or nicotine dependence when 
trained on the first half of the data and tested on the second half (left) as well as when 
trained on the second half and tested on the first half (right). Meth=methamphetamine.
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TABLE 1.
Sex Distribution and Mean Age of Case and Control Subjects, by Dependence Subgroup, in a Mega-Analysis 
of Gray Matter Volume in Substance Dependence
Group or Dependence
Subgroup
Female Age (years)
Total N N % Mean SD
All Groups
 Control 1,100
 449* 40.8 28.5* 9.9
 Case 2,140 731 34.2 33.3 10.6
Alcohol
 Control 292 99 33.9 31.3* 10.2
 Case 898 291 32.4 34.7 10.7
Nicotine
 Control 290 155* 53.4 26.1* 8.0
 Case 602 250 41.5 30.8 9.8
Cocaine
 Control 99 39* 39.4 36.0* 10.3
 Case 227 54 23.8 40.2 7.7
Methamphetamine
 Control 173 71 41.G 31.7 9.3
 Case 228 78 34.2 32.9 10.0
Cannabis
 Control 246 85 34.6 22.7* 7.5
 Case 185 58 31.4 26.5 10.0
*p<0.05.
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